Vita Life Sciences Limited

VLS

AU000000VLS8

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:33:25 28/05/2024 BST			5-day change	1st Jan Change
2.28 ^AUD	-5.00%		+5.07%	+28.09%

02-26	Vita Life Sciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023	CI

Vita Life Sciences Limited Provides Earnings Guidance for the Year Ending December 31, 2019

December 12, 2019 at 09:50 pm

Vita Life Sciences Limited provided earnings guidance for the year ending December 31, 2019. For the year ending December 31, 2019, the company expects sales of $41.0 million to $41.5 million and statutory EBIT in the range of $3.5 million to $4.0 million.

Latest news about Vita Life Sciences Limited

Vita Life Sciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-26	CI
Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023	12-14	CI
Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023	24/08/23	CI
Vita Life Sciences Limited Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23	CI
Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director	01/08/23	CI
Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending 30 June 2023	26/06/23	CI
Vita Life Sciences Limited announces an Equity Buyback for 8,475,692 shares, representing 15% of its issued share capital.	09/05/23	CI
Vita Life Sciences Limited's Equity Buyback announced on May 11, 2022, has expired with 208,000 shares, representing 0.37% for AUD 0.34 million.	08/05/23	CI
Vita Life Sciences Limited authorizes a Buyback Plan.	08/05/23	CI
Vita Life Sciences Limited Announces Demise of Gregory Ralph, Non-Executive Director	12/04/23	CI
Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2022, Payable on April 14, 2023	23/02/23	CI
Vita Life Sciences Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23/02/23	CI
Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022	28/11/22	CI
Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022	21/09/22	CI
Vita Life Sciences Limited Reports Earnings Results for the Half Year Ended June 30, 2022	26/08/22	CI
Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022	26/08/22	CI
Vita Life Sciences Expects Higher H1 Sales, Pretax Profit	03/06/22	MT
Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022	03/06/22	CI
Vita Life Sciences Limited announces an Equity Buyback for 8,325,392 shares, representing 15% of its issued share capital.	11/05/22	CI
Vita Life Sciences Limited's Equity Buyback announced on May 28, 2021, has expired.	10/05/22	CI
Vita Life Sciences Limited authorizes a Buyback Plan.	10/05/22	CI
Tranche Update on Vita Life Sciences Limited's Equity Buyback Plan announced on May 28, 2021.	24/03/22	CI
Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022	23/02/22	CI
Vita Life Sciences Limited Reports Earnings Results for the Full Year Ended December 31, 2021	23/02/22	CI
Vita Life Sciences : Expects 20% Increase in 2021 Pretax Profit on Strong Sales; Shares Jump 8%	04/10/21	MT

Chart Vita Life Sciences Limited

Duration

Period

More charts

Company Profile

Vita Life Sciences Limited (Vita Life) is a pharmaceutical and healthcare company. The Company is involved in formulating, packaging, sales and distributing vitamins and supplements. Its core business is the development and distribution of over-the-counter (OTC) medicines, as well as complementary and alternative medicines, dietary supplements and health foods under various brand names throughout Australia, Malaysia, Singapore, Thailand, Vietnam, China and Indonesia. Its brand portfolio includes Herbs of Gold, VitaHealth, VitaScience and VitaLife. Herbs of Gold brand produces premium herbal, mineral, vitamin and superfood products. VitaHealth brand offers a comprehensive range of nutritional products that cater to every health need, from inner wellness to outer radiance. VitaScience is a vivacious nutritional supplement brand that offers practitioner strength quality formulations. Its subsidiaries include Vita Healthcare Asia Pacific Sdn Bhd, Herbs of Gold Sdn Bhd and others.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VITA LIFE SCIENCES LIMITED	+28.09%	89.06M
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	354B
MERCK & CO., INC.	+15.66%	328B
ABBVIE INC.	+0.24%	277B
ASTRAZENECA PLC	+13.47%	243B
NOVARTIS AG	+7.35%	205B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	164B
PFIZER, INC.	-1.70%	164B